{"entity":{"id":"nct06396065","kind":"trial","name":"Phase III Study of AK112 for NSCLC Patients","aka":[],"tldr":"A phase 3 trial of Ivonescimab, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Summit Therapeutics, active and no longer recruiting.","summary":"Phase III Study of AK112 for NSCLC Patients is a phase 3 interventional study registered as NCT06396065 by Summit Therapeutics, with 420 participants enrolled, started 2023-05-04 and due to reach its primary completion in 2025-04-12. Interventions recorded: AK112 Injection, Placebo Injection. Conditions listed: Non-Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06396065","url":"https://clinicaltrials.gov/study/NCT06396065"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["ivonescimab","pemetrexed","carboplatin"],"companies":["summit-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct06396065-lancet-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06396065","phase":"3","setting":"A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment","sponsor":"Summit Therapeutics","started":"2023-05-04","startedType":"actual","enrolled":420,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06396065/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"}],"paper":[{"id":"paper-nct06396065-lancet-oncol-2026","kind":"paper","name":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct06396065-lancet-oncol-2026/"}]}}